Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169162 | 0.89 | HSD11B1 (0.52) | FAAHCNR2HSD11B1GPR132 | |
| SCHEMBL14105946 | 0.87 | FAAH (0.38) | FAAHCNR2HSD11B1GPR132P2RX7 | |
| SCHEMBL3773962 | 0.81 | NPC1 (0.54) | FAAHCNR2HSD11B1HSD11B2P2RX7 | |
| SCHEMBL2024608 | 0.78 | NR1H4 (0.47) | FAAHCNR2HSD11B1HSD11B2KMT2A | |
| SCHEMBL14105947 | 0.76 | HSD11B1 (0.42) | FAAHCNR2HSD11B1HSD11B2 | |
| SCHEMBL14135004 | 0.76 | HSD11B1 (0.40) | FAAHCNR2HSD11B1GPR132KMT2A | |
| SCHEMBL4556735 | 0.76 | P2RX7 (0.55) | FAAHHSD11B1HSD11B2P2RX7KMT2A | |
| SCHEMBL1168372 | 0.76 | FAAH (0.52) | FAAHCNR2HSD11B1 | |
| SCHEMBL3777993 | 0.76 | HSD11B1 (0.43) | FAAHCNR2HSD11B1HSD11B2 | |
| SCHEMBL3773939 | 0.75 | HSD11B1 (0.45) | FAAHCNR2HSD11B1HSD11B2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS ,LLC (US) | 2010-12-30 | — | — | US | claimed |
| EP-2129652-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008101907-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | claimed |
| US-8334305-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334305-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334305-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS ,LLC (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS ,LLC (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS ,LLC (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2129652-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008101907-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | FAAH 240/4885CNR2 2823/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.